GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: targeted drug combo shows promise
Disease control Recruiting nowThis study tests whether adding the drug Zolbetuximab to standard chemotherapy can help people with a specific type of advanced stomach or esophageal cancer live longer. It is for patients whose tumors have a certain protein (CLDN18.2) and who have already had one prior treatment…
Matched conditions: GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New drug combo shows promise for stomach cancer patients
Disease control Recruiting nowThis study tests two experimental drugs, AK109 and AK104, with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. The goal is to see if the combination can shrink tumors or slow disease prog…
Matched conditions: GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC